title: Pityriasis rubra pilaris: treatment with biologics - a new promising therapy?
abstract: Pityriasis rubra pilaris (PRP) includes a spectrum of rare chronic inflammatory disorders with papulosquamous eruptions of unknown cause. Different etiologies have been proposed such as vitamin A metabolism dysfunction, association with autoimmune disorders, infection or malignancies. However, PRP seems to be a polygenic skin disorder. Classical systemic treatment is empirical and includes retinoids and methotrexate; however, only few series on treatments exist. Recently there has been an increasing number of reports documenting that new biologicals and in particular TNF-α blockers are safe and effective.
authors.affiliation: Department of Dermatology, University Hospital Basel, Basel, Switzerland. ivanovak@uhbs.ch
authors.forename: Katja
authors.initials: K
authors.lastname: Ivanova
authors.forename: Peter
authors.initials: P
authors.lastname: Itin
authors.forename: Peter
authors.initials: P
authors.lastname: Haeusermann
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D010916:Pityriasis Rubra Pilaris / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D000068879:Adalimumab